title: Maximal androgen blockade versus total androgen suppression.
abstract: As long as advanced prostate cancer remains androgen-dependent, it can be treated by castration in combination with anti-androgens. When despite maximal androgen blockade (MAB), progression occurs, the anti-androgen withdrawal can result in partial remission. Otherwise corticosteroids can be used in low doses in order to suppress the androgens originating from the adrenal gland: total androgen suppression (TAS). The minimal side effects and the low cost price of this treatment are important advantages, given the fact that only few efficient cytostatic agents are actually available for hormone-escaped prostate cancer. About 30% of the patients with advanced prostate cancer that became androgen independent will show a secondary remission under low doses hydrocortisone or prednisone.
authors.affiliation: Dept. of Oncology and Urology, University Hospitals KULeuven.
authors.forename: H
authors.initials: H
authors.lastname: Dumez
authors.forename: H
authors.initials: H
authors.lastname: Van Poppel
authors.forename: L
authors.initials: L
authors.lastname: Baert
authors.forename: R
authors.initials: R
authors.lastname: Paridaens
mesh_terms: D000230:Adenocarcinoma / Q000188:drug therapy / Q000378:metabolism / Q000628:therapy*; D000726:Androgen Antagonists / Q000627:therapeutic use*; D000728:Androgens / Q000096:biosynthesis; D003131:Combined Modality Therapy; D006801:Humans; D008297:Male; D008875:Middle Aged; D009919:Orchiectomy; D017430:Prostate-Specific Antigen / Q000097:blood; D011471:Prostatic Neoplasms / Q000188:drug therapy / Q000378:metabolism / Q000628:therapy*
chemical_list: D000726:Androgen Antagonists; D000728:Androgens; D017430:Prostate-Specific Antigen